FDA approves AZ Imfinzi in new lung cancer useAstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, Share XFDA approves AZ Imfinzi in new lung cancer usehttps://pharmaphorum.com/news/fda-approves-az-imfinzi-in-new-lung-cancer-use/
AZ’s immunotherapy combo fails in phase 3 lung cancer trialAstraZeneca’s Imfinzi plus standard chemo improves overall survival in untreated extensive-stage small cell lung cancer – but a Share XAZ’s immunotherapy combo fails in phase 3 lung cancer trialhttps://pharmaphorum.com/news/azs-immunotherapy-combo-fails-in-phase-3-lung-cancer-trial/
Staying on the cutting edge of oncology advancesRapidly-changing treatment landscapes in diseases like lung cancer pose challenges for medical education providers, who need to be Share XStaying on the cutting edge of oncology advanceshttps://deep-dive.pharmaphorum.com/magazine/research-and-development-disruption-2020/cutting-edge-oncology-advances-medscape-medical-education/
Janssen antibody could be lung cancer breakthroughThe FDA thinks a dual-target antibody from Janssen could set new standards in treatment for certain patients with Share XJanssen antibody could be lung cancer breakthroughhttps://pharmaphorum.com/news/janssen-genmab-antibody-could-be-lung-cancer-breakthrough/
FDA to quickly review Roche’s chemo-free lung cancer regimenRoche’s challenge to Merck & Co’s immunotherapy Keytruda in first line lung cancer has gathered momentum after the Share XFDA to quickly review Roche’s chemo-free lung cancer regimenhttps://pharmaphorum.com/news/roche-closing-in-on-chemo-free-first-line-nsclc-regimen/
Jazz targets US launch of SCLC drug after FDA grants fast reviewPharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for Share XJazz targets US launch of SCLC drug after FDA grants fast reviewhttps://pharmaphorum.com/news/jazz-targets-us-launch-of-sclc-drug-after-fda-grants-fast-review/
FDA to quickly review Novartis’ capmatinib in rare lung cancerThe FDA has agreed to fast-track its regulatory review of Novartis’ capmatinib in a hard-to-treat form of lung Share XFDA to quickly review Novartis’ capmatinib in rare lung cancerhttps://pharmaphorum.com/news/fda-to-quickly-review-novartis-capmatinib-in-rare-lung-cancer/
Boosted by Celgene’s cash, BMS bounces back after mega-mergerBristol-Myers Squibb’s $74 billion mega-merger with Celgene seems to have been vindicated after a set of glowing full-year Share XBoosted by Celgene’s cash, BMS bounces back after mega-mergerhttps://pharmaphorum.com/news/bms/
BMS plans another tack as EU regulators knock back lung cancer comboBristol-Myers Squibb has withdrawn a European filing of its immunotherapy combination of Opdivo and Yervoy in first line Share XBMS plans another tack as EU regulators knock back lung cancer combohttps://pharmaphorum.com/news/bms-withdraws-eu-filing-for-opdivoyervoy-in-nsclc/
